Table 5 Covariate analysis

From: Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

Covariate Level Events (%) HR estimatea 95% CI p valueb
ECOG 0-Fully active 58.7% (352/600) 1.000   
1-Restricted 73.2% (246/336) 1.513 [1.280, 1.789] < 0.0001
2 or higher 70.0% (56/80) 1.624 [1.217, 2.168]  
Extra-hepatic disease prior to treatment No 59.0% (426/722) 1.000   
Yes 76.7% (234/305) 1.372 [1.149, 1.638] < 0.0001
Cirrhosis No 65.6% (463/706) 1.000   
Yes 61.4% (197/321) 1.304 [1.063, 1.599] 0.0128
Ascites No 63.6% (588/925) 1.000   
Yes 70.6% (72/102) 1.344 [1.035, 1.746] 0.0039
Tumour to liver percentage Less than 10% 59.0% (242/410) 1.000   
10%–20% 62.0% (127/205) 1.137 [0.914, 1.413] 0.0195
Greater than 20% 66.8% (147/220) 1.414 [1.143, 1.750]  
Unknown 75.0% (144/192) 1.098 [0.879, 1.373]  
Location of liver tumours Bilobar 71.4% (419/587) 1.000   
Left only 57.0% (57/100) 0.790 [0.589, 1.059] 0.0024
Right only 54.3% (184/339) 0.694 [0.572, 0.843]  
Prior chemotherapy: number of lines 0 57.4% (296/516) 1.000   
1 64.4% (123/191) 1.176 [0.931, 1.485] < 0.0001
2–5 76.8% (172/224) 1.855 [1.493, 2.303]  
6 or more 72.5% (66/91) 1.355 [1.010, 1.818]  
  1. aA hazard ratio above 1 implies a higher rate of non-survival for that category compared to the reference category (for which the hazard ratio is 1.000). Selection of covariates based on a stepwise procedure. Variables that did not qualify (p > 0.05) were: sex (p = 0.2800), prior systemic therapy (p = 0.2664), prior hepatic procedures (p = 0.0895) and number of liver tumours (p = 0.0964)
  2. bP values are from global Wald test